Minute Insight: Biofourmis Raises $300M To Fund Digital Drug-Companion Therapies
The Boston company will use the new investment to continue scaling its virtual care business. Biofourmis also announced that medtech veteran Omar Ishrak is joining the company’s board as its chairman.
You may also be interested in...
An internal investigation found that the company’s leadership may have directed employees to improperly account for sales-incentive payments. As a result, the company has been unable to file its quarterly report for the first quarter of 2022 with the SEC.
Analysts believe the company’s arrythmia mapping technology could potentially disrupt the electrophysiology mapping market, but are disappointed with Acutus’ growth so far.
Medtech Insight caught up again with iRhythm CEO Quentin Blackford about his vision for the company as it plans for the next five to ten years of expansion in the remote cardiac monitoring and arrhythmia diagnostics market.